• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection.

作者信息

Daskapan Alper, de Lange Wiel C M, Akkerman Onno W, Kosterink Jos G W, van der Werf Tjip S, Stienstra Ymkje, Alffenaar Jan-Willem C

机构信息

University of Groningen, University Medical Center Groningen, Dept of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands.

University of Groningen, University Medical Center Groningen, Dept of Pulmonary Diseases and Tuberculosis, Groningen, The Netherlands.

出版信息

Eur Respir J. 2015 Feb;45(2):569-71. doi: 10.1183/09031936.00142614.

DOI:10.1183/09031936.00142614
PMID:25653274
Abstract
摘要

相似文献

1
The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection.治疗药物监测在结核病与艾滋病病毒合并感染患者个体化药物剂量及暴露量测定中的作用
Eur Respir J. 2015 Feb;45(2):569-71. doi: 10.1183/09031936.00142614.
2
The role of therapeutic drug monitoring in individualised drug dosage and exposure measurement in tuberculosis and HIV co-infection.治疗药物监测在结核病与艾滋病病毒合并感染的个体化药物剂量及暴露量测量中的作用。
Eur Respir J. 2015 Feb;45(2):571-4. doi: 10.1183/09031936.00157914.
3
ERS/WHO Tuberculosis Consilium assistance in extensively drug-resistant tuberculosis.欧洲呼吸学会/世界卫生组织结核病咨询委员会对广泛耐药结核病的援助。
Eur Respir J. 2015 Jan;45(1):294-5. doi: 10.1183/09031936.00107814.
4
Managing an extensively drug-resistant tuberculosis outbreak: the public health face of the medal.应对广泛耐药结核病疫情：奖章背后的公共卫生工作
Eur Respir J. 2015 Jan;45(1):292-4. doi: 10.1183/09031936.00134114.
5
ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use.欧洲呼吸学会/世界卫生组织结核病咨询委员会对一名儿童广泛耐药结核病管理的援助：使用德拉马尼的同情用药案例研究
Eur Respir J. 2014 Sep;44(3):811-5. doi: 10.1183/09031936.00060414. Epub 2014 May 15.
6
Bedaquiline and Delamanid in Children With XDR Tuberculosis: What is prolonged QTc?贝达喹啉和德拉马尼在耐多药结核病患儿中的应用：何为 QTc 延长？
Pediatr Infect Dis J. 2020 Jun;39(6):512-513. doi: 10.1097/INF.0000000000002601.
7
Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis.跨境，对一例广泛耐药结核病患者进行极具个体化的治疗。
Eur Respir J. 2018 Mar 22;51(3). doi: 10.1183/13993003.02490-2017. Print 2018 Mar.
8
Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.贝达喹啉和德拉马尼联合治疗 5 例广泛耐药肺结核患者。
Emerg Infect Dis. 2017 Oct;23(10):1718-21. doi: 10.3201/eid2310.170834. Epub 2017 Oct 17.
9
Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers.广泛耐药结核病的个体化管理：诊断、治疗及生物标志物
Expert Rev Anti Infect Ther. 2017 Jan;15(1):11-21. doi: 10.1080/14787210.2017.1247692. Epub 2016 Oct 24.
10
Classification of antituberculosis drugs: a new proposal based on the most recent evidence.抗结核药物分类：基于最新证据的新提议。
Eur Respir J. 2015 Oct;46(4):887-93. doi: 10.1183/13993003.00432-2015.

引用本文的文献

1
Therapeutic drug monitoring in tuberculosis.结核病治疗药物监测。
Eur J Clin Pharmacol. 2024 Nov;80(11):1659-1684. doi: 10.1007/s00228-024-03749-8. Epub 2024 Sep 6.
2
Development of a population pharmacokinetic model of pyrazinamide to guide personalized therapy: impacts of geriatric and diabetes mellitus on clearance.吡嗪酰胺群体药代动力学模型的建立以指导个体化治疗：老年和糖尿病对清除率的影响
Front Pharmacol. 2023 May 26;14:1116226. doi: 10.3389/fphar.2023.1116226. eCollection 2023.
3
Development and validation of a liquid chromatography-tandem mass spectrometry method for quantifying delamanid and its metabolite in small hair samples.
开发并验证了一种液相色谱-串联质谱法，用于从小发样中定量检测德拉马尼及其代谢物。
J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Apr 15;1169:122467. doi: 10.1016/j.jchromb.2020.122467. Epub 2020 Dec 10.
4
Association of anti-tuberculosis drug concentrations in hair and treatment outcomes in MDR- and XDR-TB.耐多药和广泛耐药结核病患者头发中抗结核药物浓度与治疗结果的关联
ERJ Open Res. 2019 Apr 26;5(2). doi: 10.1183/23120541.00046-2019. eCollection 2019 Apr.
5
High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre.高剂量利福平治疗结核病：荷兰结核病中心的经验。
PLoS One. 2019 Mar 14;14(3):e0213718. doi: 10.1371/journal.pone.0213718. eCollection 2019.
6
A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs.HIV 感染对一线抗结核药物药代动力学影响的系统评价。
Clin Pharmacokinet. 2019 Jun;58(6):747-766. doi: 10.1007/s40262-018-0716-8.
7
Recent developments in the diagnosis and management of tuberculosis.结核病的诊断和管理的最新进展。
NPJ Prim Care Respir Med. 2016 Nov 3;26:16078. doi: 10.1038/npjpcrm.2016.78.
8
New anti-tuberculosis drugs and regimens: 2015 update.新型抗结核药物与治疗方案：2015年更新
ERJ Open Res. 2015 May 6;1(1). doi: 10.1183/23120541.00010-2015. eCollection 2015 May.
9
Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?肺结核治疗的新兴策略：前景与局限？
Korean J Intern Med. 2016 Jan;31(1):15-29. doi: 10.3904/kjim.2016.31.1.15. Epub 2015 Dec 28.
10
Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis.结核病患者中利福平治疗药物监测的药代动力学建模与最佳采样策略
Antimicrob Agents Chemother. 2015 Aug;59(8):4907-13. doi: 10.1128/AAC.00756-15. Epub 2015 Jun 8.